Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2011

Open Access 01-12-2011 | Research article

Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil

Authors: Weihu Shang, Jinping Qiao, Chenxin Gu, Wei Yin, Jinglei Du, Wei Wang, Meilin Zhu, Mei Han, Weidong Lu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2011

Login to get access

Abstract

Background

Botanical medicines are increasingly combined with chemotherapeutics as anticancer drug cocktails. This study aimed to assess the chemotherapeutic potential of an extract of Taxus cuspidata (TC) needles and twigs produced by artificial cuttage and its co-effects as a cocktail with 5-fluorouracil (5-FU).

Methods

Components of TC extract were identified by HPLC fingerprinting. Cytotoxicity analysis was performed by MTT assay or ATP assay. Apoptosis studies were analyzed by H & E, PI, TUNEL staining, as well as Annexin V/PI assay. Cell cycle analysis was performed by flow cytometry. 5-FU concentrations in rat plasma were determined by HPLC and the pharmacokinetic parameters were estimated using 3p87 software. Synergistic efficacy was subjected to median effect analysis with the mutually nonexclusive model using Calcusyn1 software. The significance of differences between values was estimated by using a one-way ANOVA.

Results

TC extract reached inhibition rates of 70-90% in different human cancer cell lines (HL-60, BGC-823, KB, Bel-7402, and HeLa) but only 5-7% in normal mouse T/B lymphocytes, demonstrating the broad-spectrum anticancer activity and low toxicity to normal cells of TC extract in vitro. TC extract inhibited cancer cell growth by inducing apoptosis and G2/M cell cycle arrest. Most interestingly, TC extract and 5-FU, combined as a cocktail, synergistically inhibited the growth of cancer cells in vitro, with Combination Index values (CI) ranging from 0.90 to 0.26 at different effect levels from IC50 to IC90 in MCF-7 cells, CI ranging from 0.93 to 0.13 for IC40 to IC90 in PC-3M-1E8 cells, and CI < 1 in A549 cells. In addition, the cocktail had lower cytotoxicity in normal human cell (HEL) than 5-FU used alone. Furthermore, TC extract did not affect the pharmacokinetics of 5-FU in rats.

Conclusions

The combinational use of the TC extract with 5-FU displays strong cytotoxic synergy in cancer cells and low cytotoxicity in normal cells. These findings suggest that this cocktail may have a potential role in cancer treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gediya LK, Njar VCO: Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin Drug Dis. 2009, 4 (11): 1099-1111.CrossRef Gediya LK, Njar VCO: Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin Drug Dis. 2009, 4 (11): 1099-1111.CrossRef
2.
go back to reference Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB: Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer. 2010, 10: 175-CrossRefPubMedPubMedCentral Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB: Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer. 2010, 10: 175-CrossRefPubMedPubMedCentral
3.
go back to reference Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-2550.CrossRefPubMed Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-2550.CrossRefPubMed
4.
go back to reference Chiu GNC, Wong MY, Ling LU, Shaikh IM, Tan KB, Chaudhury A, Tan BJ: Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr Drug Metab. 2009, 10 (8): 861-874.CrossRefPubMed Chiu GNC, Wong MY, Ling LU, Shaikh IM, Tan KB, Chaudhury A, Tan BJ: Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr Drug Metab. 2009, 10 (8): 861-874.CrossRefPubMed
5.
go back to reference Koppikar SJ, Choudhari AS, Suryavanshi SA, Kumari S, Chattopadhyay S, Ghanekar RK: Aqueous Cinnamon Extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential. BMC Cancer. 2010, 10: 210-CrossRefPubMedPubMedCentral Koppikar SJ, Choudhari AS, Suryavanshi SA, Kumari S, Chattopadhyay S, Ghanekar RK: Aqueous Cinnamon Extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential. BMC Cancer. 2010, 10: 210-CrossRefPubMedPubMedCentral
6.
go back to reference Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH: In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 2007, 65 (3): 289-299.CrossRefPubMed Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH: In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 2007, 65 (3): 289-299.CrossRefPubMed
7.
go back to reference Mijatovic SA, Timotijevic GS, Miljkovic DM, Radovic JM, Maksimovic-Ivanic DD, Dekanski DP, Stosic-Grujicic SD: Multiple antimelanoma potential of dry olive leaf extract. Int J Cancer. 2011, 128 (8): 1955-1965.CrossRefPubMed Mijatovic SA, Timotijevic GS, Miljkovic DM, Radovic JM, Maksimovic-Ivanic DD, Dekanski DP, Stosic-Grujicic SD: Multiple antimelanoma potential of dry olive leaf extract. Int J Cancer. 2011, 128 (8): 1955-1965.CrossRefPubMed
8.
go back to reference Wagner H: Natural products chemistry and phytomedicine in the 21(st) century: new developments and challenges. Pure Appl Chem. 2005, 77 (1): 1-6.CrossRef Wagner H: Natural products chemistry and phytomedicine in the 21(st) century: new developments and challenges. Pure Appl Chem. 2005, 77 (1): 1-6.CrossRef
9.
go back to reference Lei XY, Kong L, Su XY, Guo M, Zou HF: Biological fingerprinting analysis of interaction between taxoids in Taxus and microtubule protein by microdialysis coupled, with high-performance liquid chromatography/mass spectrometry for screening antimicrotubule agents. Chem Res Chinese U. 2008, 24 (4): 411-419.CrossRef Lei XY, Kong L, Su XY, Guo M, Zou HF: Biological fingerprinting analysis of interaction between taxoids in Taxus and microtubule protein by microdialysis coupled, with high-performance liquid chromatography/mass spectrometry for screening antimicrotubule agents. Chem Res Chinese U. 2008, 24 (4): 411-419.CrossRef
10.
go back to reference Hsiao WLW, Liu LA: The role of traditional Chinese herbal medicines in cancer therapy - from TCM theory to mechanistic insights. Planta Med. 2010, 76 (11): 1118-1131.CrossRefPubMed Hsiao WLW, Liu LA: The role of traditional Chinese herbal medicines in cancer therapy - from TCM theory to mechanistic insights. Planta Med. 2010, 76 (11): 1118-1131.CrossRefPubMed
11.
go back to reference Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang ZL, Su T, Cheng YC: Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009, 29 (10): 4083-4092.PubMed Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang ZL, Su T, Cheng YC: Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009, 29 (10): 4083-4092.PubMed
12.
go back to reference Qi FH, Li AY, Inagaki Y, Gao JJ, Li JJ, Kokudo N, Li XK, Tang W: Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010, 4 (6): 297-307.PubMed Qi FH, Li AY, Inagaki Y, Gao JJ, Li JJ, Kokudo N, Li XK, Tang W: Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010, 4 (6): 297-307.PubMed
13.
go back to reference Wagner H: Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia. 2011, 82 (1): 34-37.CrossRefPubMed Wagner H: Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia. 2011, 82 (1): 34-37.CrossRefPubMed
14.
go back to reference Kobayashi J, Shigemori H: Bioactive taxoids from the Japanese Yew Taxus cuspidata. Med Res Rev. 2002, 22 (3): 305-328.CrossRefPubMed Kobayashi J, Shigemori H: Bioactive taxoids from the Japanese Yew Taxus cuspidata. Med Res Rev. 2002, 22 (3): 305-328.CrossRefPubMed
15.
go back to reference Wang LY, Bai LM, Tokunaga D, Watanabe Y, Hasegawa T, Sakai J, Tang WX, Bai YH, Hirose K, Yamori T: The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity. J Wood Sci. 2008, 54 (5): 390-401.CrossRef Wang LY, Bai LM, Tokunaga D, Watanabe Y, Hasegawa T, Sakai J, Tang WX, Bai YH, Hirose K, Yamori T: The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity. J Wood Sci. 2008, 54 (5): 390-401.CrossRef
16.
go back to reference Tachibana S, Ishikawa H, Itoh K: Antifungal activities of compounds isolated from the leaves of Taxus cuspidata var. nana against plant pathogenic fungi. J Wood Sci. 2005, 51 (2): 181-184.CrossRef Tachibana S, Ishikawa H, Itoh K: Antifungal activities of compounds isolated from the leaves of Taxus cuspidata var. nana against plant pathogenic fungi. J Wood Sci. 2005, 51 (2): 181-184.CrossRef
17.
go back to reference Liang M, Liu WH, Zhang XC, Wang XJ, Yuan CS: The anticancer study of DaKeSu (tablet). Chinese Tradit Pat Med. 1998, 20 (9): 43-(In Chinese) Liang M, Liu WH, Zhang XC, Wang XJ, Yuan CS: The anticancer study of DaKeSu (tablet). Chinese Tradit Pat Med. 1998, 20 (9): 43-(In Chinese)
18.
go back to reference Yan XM, Yan XF: The efficacy observation of DaKeSu used in clinical. Shandong Med Ind. 2001, 20 (4): 52-53. (In Chinese) Yan XM, Yan XF: The efficacy observation of DaKeSu used in clinical. Shandong Med Ind. 2001, 20 (4): 52-53. (In Chinese)
19.
go back to reference Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3 (5): 330-338.CrossRefPubMed Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3 (5): 330-338.CrossRefPubMed
20.
go back to reference Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002, 7 (4): 288-323.CrossRefPubMed Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002, 7 (4): 288-323.CrossRefPubMed
21.
go back to reference Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004, 22 (11): 2214-2232.CrossRefPubMed Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004, 22 (11): 2214-2232.CrossRefPubMed
22.
go back to reference Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LOM, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer - a novel, safe, and effective regimen. Am J Clin Oncol-Canc. 1999, 22 (6): 580-586.CrossRef Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LOM, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer - a novel, safe, and effective regimen. Am J Clin Oncol-Canc. 1999, 22 (6): 580-586.CrossRef
23.
go back to reference Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999, 85 (2): 295-301.CrossRefPubMed Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999, 85 (2): 295-301.CrossRefPubMed
24.
go back to reference Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003, 97 (2): 412-418.CrossRefPubMed Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003, 97 (2): 412-418.CrossRefPubMed
25.
go back to reference Zhao L, Chen Z, Wang J, Yang L, Zhao Q, Wang J, Qi Q, Mu R, You QD, Guo QL: Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol. 2010, 65: 481-489.CrossRefPubMed Zhao L, Chen Z, Wang J, Yang L, Zhao Q, Wang J, Qi Q, Mu R, You QD, Guo QL: Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol. 2010, 65: 481-489.CrossRefPubMed
26.
go back to reference Zeng F, Liu XG, Li YC, Chen G, Wang YK, Zhou SQ, Zhu WY, Huang YY, Zhou JH, Li SB, Zhang YK: Chan-Yu-Bao-Yuan-Tang and 5-fluorouracil synergistically induce apoptosis by means of the caspase-3 signaling pathway in lung and cervical cancer cells. Mol Med Rep. 2011, 4 (1): 113-120.PubMed Zeng F, Liu XG, Li YC, Chen G, Wang YK, Zhou SQ, Zhu WY, Huang YY, Zhou JH, Li SB, Zhang YK: Chan-Yu-Bao-Yuan-Tang and 5-fluorouracil synergistically induce apoptosis by means of the caspase-3 signaling pathway in lung and cervical cancer cells. Mol Med Rep. 2011, 4 (1): 113-120.PubMed
27.
go back to reference Han M, Li JF, Tan Q, Sun YY, Wang YY: Limitations of the use of MTT assay for screening in drug discovery. J Chin Pharmaceu Sci. 2010, 19: 195-200. Han M, Li JF, Tan Q, Sun YY, Wang YY: Limitations of the use of MTT assay for screening in drug discovery. J Chin Pharmaceu Sci. 2010, 19: 195-200.
28.
go back to reference Sun Y, Wang W, Sun YY, Han M: Synthesis and biological evaluation of a novel human stem/progenitor cells proliferation activator: (5-mercapto-1,3,4-oxadiazol-2-yl)phenyl thiosemicarbazide (Stemazole). Eur J Med Chem. 2011, 46: 2930-2936.CrossRefPubMed Sun Y, Wang W, Sun YY, Han M: Synthesis and biological evaluation of a novel human stem/progenitor cells proliferation activator: (5-mercapto-1,3,4-oxadiazol-2-yl)phenyl thiosemicarbazide (Stemazole). Eur J Med Chem. 2011, 46: 2930-2936.CrossRefPubMed
29.
go back to reference Qiao JP, Gu CX, Shang WH, Du JL, Yin W, Zhu ML, Wang W, Han M, Lu WD: Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem Toxicol. 2011, 49: 1410-1415.CrossRefPubMed Qiao JP, Gu CX, Shang WH, Du JL, Yin W, Zhu ML, Wang W, Han M, Lu WD: Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem Toxicol. 2011, 49: 1410-1415.CrossRefPubMed
30.
go back to reference Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed
31.
go back to reference Fu YJ, Sun R, Zu YG, Li SM, Liu W, Efferth T, Gu CB, Zhang L, Luo H: Simultaneous determination of main taxoids in Taxus needles extracts by solid-phase extraction-high-performance liquid chromatography with pentafluorophenyl column. Biomed Chromatogr. 2009, 23 (1): 63-70.CrossRefPubMed Fu YJ, Sun R, Zu YG, Li SM, Liu W, Efferth T, Gu CB, Zhang L, Luo H: Simultaneous determination of main taxoids in Taxus needles extracts by solid-phase extraction-high-performance liquid chromatography with pentafluorophenyl column. Biomed Chromatogr. 2009, 23 (1): 63-70.CrossRefPubMed
32.
go back to reference Jenniskens LHD, vanRozendaal ELM, vanBeek TA, Wiegerinck PHG, Scheeren HW: Identification of six taxine alkaloids from Taxus baccata needles. J Nat Prod. 1996, 59 (2): 117-123.CrossRef Jenniskens LHD, vanRozendaal ELM, vanBeek TA, Wiegerinck PHG, Scheeren HW: Identification of six taxine alkaloids from Taxus baccata needles. J Nat Prod. 1996, 59 (2): 117-123.CrossRef
33.
go back to reference Zu YG, Fu YJ, Li SM, Sun R, Li QY, Schwarz G: Rapid separation of four main taxoids in Taxus species by a combined LLP-SPE-HPLC (PAD) procedure. J Sep Sci. 2006, 29 (9): 1237-1244.CrossRefPubMed Zu YG, Fu YJ, Li SM, Sun R, Li QY, Schwarz G: Rapid separation of four main taxoids in Taxus species by a combined LLP-SPE-HPLC (PAD) procedure. J Sep Sci. 2006, 29 (9): 1237-1244.CrossRefPubMed
34.
go back to reference Wang YF, Yu SH, Dong M, Zhang ML, Huo CH, Shi QW: Chemical studies on Taxus cuspidata. Chem Biodivers. 2010, 7 (7): 1698-1716.CrossRefPubMed Wang YF, Yu SH, Dong M, Zhang ML, Huo CH, Shi QW: Chemical studies on Taxus cuspidata. Chem Biodivers. 2010, 7 (7): 1698-1716.CrossRefPubMed
35.
go back to reference Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996, 74 (5): 704-710.CrossRefPubMedPubMedCentral Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996, 74 (5): 704-710.CrossRefPubMedPubMedCentral
36.
go back to reference Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006, 119 (4): 783-791.CrossRefPubMed Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006, 119 (4): 783-791.CrossRefPubMed
37.
go back to reference Chavez ML, Jordan MA, Chave PI: Evidence-based drug-herbal interactions. Life Sci. 2006, 78: 2146-2157.CrossRefPubMed Chavez ML, Jordan MA, Chave PI: Evidence-based drug-herbal interactions. Life Sci. 2006, 78: 2146-2157.CrossRefPubMed
38.
go back to reference Rapaka RS, Coates PM: Dietary supplements and related products: a brief summary. Life Sci. 2006, 78: 2026-2032.CrossRefPubMed Rapaka RS, Coates PM: Dietary supplements and related products: a brief summary. Life Sci. 2006, 78: 2026-2032.CrossRefPubMed
39.
go back to reference Saif MW, Choma A, Salamone SJ, Chu E: Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009, 101: 1543-1552.CrossRefPubMed Saif MW, Choma A, Salamone SJ, Chu E: Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009, 101: 1543-1552.CrossRefPubMed
40.
go back to reference Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM: Clinical response and plasma-levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978, 38: 719-724.CrossRefPubMedPubMedCentral Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM: Clinical response and plasma-levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978, 38: 719-724.CrossRefPubMedPubMedCentral
41.
go back to reference Vogel S, Presant C, Ratkin G, Klarhr C: Phase I study of infusion 5-fluorouracil (5FU) plus thymidine (T). Proc Am Assoc Cancer Res. 1978, 19: 232- Vogel S, Presant C, Ratkin G, Klarhr C: Phase I study of infusion 5-fluorouracil (5FU) plus thymidine (T). Proc Am Assoc Cancer Res. 1978, 19: 232-
42.
go back to reference Jennewein S, Croteau R: Taxol: biosynthesis, molecular genetics, and biotechnological applications. Appl Microbiol Biotechnol. 2001, 57: 13-19.CrossRefPubMed Jennewein S, Croteau R: Taxol: biosynthesis, molecular genetics, and biotechnological applications. Appl Microbiol Biotechnol. 2001, 57: 13-19.CrossRefPubMed
Metadata
Title
Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil
Authors
Weihu Shang
Jinping Qiao
Chenxin Gu
Wei Yin
Jinglei Du
Wei Wang
Meilin Zhu
Mei Han
Weidong Lu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2011
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-11-123

Other articles of this Issue 1/2011

BMC Complementary Medicine and Therapies 1/2011 Go to the issue